Article
UPDATED: Gilead CEO Dan O'Day's $21B M&A deal to buy Immunomedics gets some harsh reviews
Rating:
0.0
Views:
71
Likes:
1
Library:
1
After a wild, 4-year roller coaster ride, ImmunoMedics $IMMU is getting its fairy-tale ending after all. Sunday evening Gilead $GILD put the weekend rumors to rest and announced its agreement to buy out the company for $21 billion, which gives the big biotech Trodelvy, newly approved for metastatic triple negative
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value